GR-891

GR-891 (22.5-90 µM; 6 days) inhibits proliferation of human rhabdomyosarcoma RD cells in a time- and dose-dependent manner, with >90% cell viability maintained across tested concentrations after 6 days of continuous treatment, and irreversible growth suppression following retreatment^[2].
GR-891 (22.5-45 µM; 6 days) induces terminal myogenic differentiation in human rhabdomyosarcoma RD cells, characterized by morphological, SEM, and TEM features of mature muscle cells, including formation of myotube-like giant cells that represent up to 65% of the cell population after 6 days of treatment^[2].
GR-891 (22.5-90 µM; 6 days) modulates intermediate filament protein expression in human rhabdomyosarcoma RD cells, with 22.5 µM and 45 µM causing significant increases in desmin-positive cells (to 68.8% and 63.0%, respectively) and significant decreases in vimentin-positive cells (to 40.8% and 57.5%, respectively), consistent with myogenic differentiation^[2].
GR-891 (22.5-90 µM; 6 days) does not modify mdr1 mRNA expression in human rhabdomyosarcoma RD cells after 6 days of treatment at concentrations of 22.5, 45, or 90 µmol l^-1[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.